In the field of drug registration in Australia, the electronic Common Technical Document (eCTD) has become a core format to improve the efficiency and standardization of submissions. As a professional institution specializing in eCTD publishing and drug registration services, we have combed through the key steps of the full process by integrating the User guide on how to submit data in the electronic Common Technical Document (eCTD) format officially released by the Therapeutic Goods Administration (TGA) of Australia, and provide one-stop solutions to help your drugs quickly obtain the TGA approval.
I. Current Implementation Status of eCTD in Australia
1. Application Scope and Recommendation Level of eCTD
eCTD is recommended by TGA for all new registration applications and variation applications for prescription medicines. It can also be used for various types of submissions, including biological products, over-the-counter (OTC) drugs, registered complementary medicines, assessed listed medicines, listed medicine ingredients, and master files.
Note: Once the first submission sequence under a certain e-ID (e-Identifier) adopts the eCTD format, all subsequent sequences must continue to use this format; otherwise, it may lead to processing delay, or the sequence rejected.
2. Current Mainstream Standards: v3.1 and v3.2
Current Standard: TGA has accepted and published the eCTD specifications and validation standards v3.1 for the Australian regional Module 1. Relevant sample documents and templates can be obtained from the TGA official website.
New Version Dynamics: On September 13, 2024, TGA officially released the eCTD AU Module 1 & Regional Information v3.2, which will come into effect on February 1, 2025, with a 6-month transition period. By then, all new submissions and follow-up reports must comply with the new v3.2 specifications.
3. Evolution of eCTD v4.0
TGA is advancing the technical pilot of the eCTD 4.0 version, and it is expected to launch a voluntary adoption phase in 2026 to allow the industry to adapt to the new standards in advance. The specific implementation date of the mandatory adoption phase has not yet been finally determined. Once officially announced, all applicants must submit full sets of registration and change documents in the eCTD 4.0 format.
II. Six Core Steps of eCTD Submission (with Practical Key Points)
1. Confirm eCTD Applicability
Clarify whether the application project is suitable for the eCTD model (prescription drugs are mandatory, and other categories are optional) to avoid submission obstacles due to format errors.
2. Obtain Client ID
Purpose: As a required field in the XML envelope. It is used to group all sequences from one sponsor (client) together.
Path: Apply online through the TGA Business Services Portal, requiring advance enterprise registration.
3. Apply for e-Identifier (e-ID)
Uniqueness Rule: Each applicant and active ingredient (or combination) corresponds to a unique e-ID, covering all dosage forms, specifications, trade names, and manufacturers.
Format Requirement: Start with "e" (if migrating from the NeeS format, change the original "n" to "e").
Application Method:
Email to eSubmissions@health.gov.au (subject line: "Request for e-Identifier").
In your email, include: company name (consistent with Client ID), active ingredient(s) names, proposed application type (e.g., "Type A - New Drug Application" or “Drug Master FIle”).
4. Compile and Publish Submission Sequences
Required Items for XML Envelope:
e-ID, Client ID, approved name(s) of the active ingredients, trade name(s) (or proposed trade name(s)) - if no trade name is available, include the approved name in this field, submission or application number(s), sequence number, related sequence number, regulatory activity lead, sequence type, sequence description, submission mode - currently always 'single', contact email address, current ARTG number(s) , if applicable.
Technical Requirements:
Compile and publish your sequence with support from your eCTD software vendor or consultant. After publication, files are prohibited from being modified arbitrarily to avoid validation errors.
5. Strictly Validate Submission Sequences
6. Submit Submission Sequences
File Format: Compress into a single ZIP file named "e-ID" (e.g., e123456), containing a subfolder titled with "sequence numbers" (e.g., 0001).
Submission Methods:
≤30MB: Send by email to the eSubmissions team (note: do not send to individual evaluators);
≤100MB: Upload through the TGA Business Services Portal (TBS);
Extra-large files: Post in a USB or non-rewritable CD or DVD.
III. Professional Service by BrilliantMed
1. Deep Industry Experience
Team members all have many years of TGA project experience and are familiar with the structural requirements of the Australian regional Modules 1/2–5 and the XML packaging process.
Successfully supported many multinational pharmaceutical, generic, and biopharmaceutical companies in completing TGA registrations and variation submissions.
2. Full-Process Technical Support
Registration Document Optimization: Optimize registration documents (including Word and PDF) according to TGA requirements to achieve electronic readiness.
Registration Data Publishing: Publish eCTD in strict accordance with TGA's latest specifications (including v3.2 and future v4.0), and accurately generate XML and envelopes.
Automated Validation and Testing: Use industry-leading eCTD validation software to perform pre-validation and troubleshoot common errors.
Lifecycle Management and Submission: Plan a reasonable sequence strategy (Sequence Type/Description) for post-launch lifecycle management, and package sequences into .zip files as required for submission through the TGA Business Services Portal or by mail/CD/DVD.
3. Tailor-Made Processes and Training
Design optimal eCTD publishing and full lifecycle management processes for clients' internal system environments and process systems.
Provide eCTD tool usage training and TGA registration strategy seminars to help clients' internal teams quickly master core skills and formulate registration strategies.
If you are planning or conducting drug registration in Australia, please feel free to contact us. With our professional capabilities and rich experience, we will help you complete TGA eCTD submissions with the highest efficiency and lowest risk, and seize the opportunity in the Australian market.
Enclosure: Link to TGA eCTD Official Guide
https://www.tga.gov.au/resources/resource/user-guide/submitting-data-ectd-format
(Note: The content of this article is organized based on TGA's public guidelines. For specific submission requirements, please refer to the latest official notices.)
